Expression of Tumor Markers in Circulating Tumor Cells of Metastatic Hormone-sensitive Prostate Cancer

Inclusion Criteria: 1. Male patients; 2. 18 yrs and older, and 80 yrs and younger; 3. Histologically or cytologically proven prostate adenocarcinoma; 4. Imaging examinations including Emission Computed Tomography (ECT),Positron Emission Tomography (PET),Computed Tomography(CT)and Magnetic Resonance Imaging (MRI) revealed non-regional lymph node metastasis, bone metastasis, or visceral metastasis; 5. Not yet receiving hormonal therapy; 6. Not yet receiving chemotherapy previously; 7. Not yet receiving radical prostatectomy, radiotherapy, or transurethral resection of the prostate (TURP) previously; 8. Patients are willing to participate and can be followed up regularly； Exclusion Criteria: 1. Received radical prostatectomy, radiotherapy, or transurethral resection of the prostate (TURP) previously; 2. Received androgen deprivation therapy (including surgical castration, medical castration, anti-androgen therapy, and maximum androgen blockade) before inclusion; 3. Patients received chemotherapy previously; 4. Combined with other malignant tumor history (in addition to the skin basal cell carcinoma or other tumors that have been cured more than five years);